(E)-4-((2-(7-methoxynaphthalen-1-yl)ethyl)amino)-4-oxobut-2-enoic acid | 1595280-10-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (E)-4-((2-(7-methoxynaphthalen-1-yl)ethyl)amino)-4-oxobut-2-enoic acid
• 英文别名: (E)-4-[2-(7-methoxynaphthalen-1-yl)ethylamino]-4-oxobut-2-enoic acid
• CAS: 1595280-10-6
• 化学式: C₁₇H₁₇NO₄
• 分子量: 299.326
• InChiKey: IBZOQUVBPKZXST-BQYQJAHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-(7-甲氧基萘-1-基)乙腈 在 sodium tetrahydroborate 、 二碳酸二叔丁酯 、 nickel dichloride 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 18.0h， 生成 (E)-4-((2-(7-methoxynaphthalen-1-yl)ethyl)amino)-4-oxobut-2-enoic acid
  参考文献：
  名称：

  Synthesis and evaluation of amide side-chain modified Agomelatine analogues as potential antidepressant-like agents

  摘要：

  In this work, nineteen analogues of Agomelatine were readily synthesized through structural modification of the acetamide side-chain starting from the key common intermediate 2-(7-methoxynaphthalen-1-yl) ethanamine (3), which was prepared from commercially available compound 2-(7-methoxynaphthalen-1-yl) acetonitrile (2) in two steps. Corticosterone-induced PC12 pheochromocytoma cells phenotypic in vitro model was utilized to evaluate their potential antidepression activities. Imide compound 4a and acylamino carboxylic acid analogue 5b showed good protective effects on traumatic PC12 cells with protection rates of 34.2% and 23.2%, respectively. Further in vivo assessments in C57 mice FST (forced swim test) model demonstrated that compound 4a significantly reduced the immobility time of the tested subjects, indicating antidepressant- like activity. Preliminary toxicity assays conducted on human normal liver L02 cells and embryonic kidney 293 cells suggested a relatively low safety risk for compound 4a compared with the marketed drugs Agomelatine and Fluoxetine. The promising antidepressant-like efficacy of compound 4a, together with the relatively low toxicity to the normal tested cells and high liability of diffusion through the blood-brain barrier (BBB), presents us insights of exploration of me-better drug candidates of Agomelatine. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.02.065

文献信息

• Synthesis and evaluation of amide side-chain modified Agomelatine analogues as potential antidepressant-like agents
  作者：Ying Chang、Weiyi Pi、Wei Ang、Yuanyuan Liu、Chunlong Li、Jiajia Zheng、Li Xiong、Tao Yang、Youfu Luo

  DOI：10.1016/j.bmcl.2014.02.065

  日期：2014.4

  In this work, nineteen analogues of Agomelatine were readily synthesized through structural modification of the acetamide side-chain starting from the key common intermediate 2-(7-methoxynaphthalen-1-yl) ethanamine (3), which was prepared from commercially available compound 2-(7-methoxynaphthalen-1-yl) acetonitrile (2) in two steps. Corticosterone-induced PC12 pheochromocytoma cells phenotypic in vitro model was utilized to evaluate their potential antidepression activities. Imide compound 4a and acylamino carboxylic acid analogue 5b showed good protective effects on traumatic PC12 cells with protection rates of 34.2% and 23.2%, respectively. Further in vivo assessments in C57 mice FST (forced swim test) model demonstrated that compound 4a significantly reduced the immobility time of the tested subjects, indicating antidepressant- like activity. Preliminary toxicity assays conducted on human normal liver L02 cells and embryonic kidney 293 cells suggested a relatively low safety risk for compound 4a compared with the marketed drugs Agomelatine and Fluoxetine. The promising antidepressant-like efficacy of compound 4a, together with the relatively low toxicity to the normal tested cells and high liability of diffusion through the blood-brain barrier (BBB), presents us insights of exploration of me-better drug candidates of Agomelatine. (C) 2014 Elsevier Ltd. All rights reserved.